Y-mAbs Therapeutics Inc Investor Relations Material
Latest events
Q4 2023
Y-mAbs Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Y-mAbs Therapeutics Inc
Access all reports
Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Our clinical programs are focused on DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Key slides for Y-mAbs Therapeutics Inc
J.P. Morgan 42nd Annual Healthcare Conference 2024
Y-mAbs Therapeutics Inc
Corporate Presentation
Y-mAbs Therapeutics Inc
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States